Herein we report the development of a new periodate-based reactive assay system for the fluorescent detection of the cis-diol metabolites produced by Rieske dioxygenases. This sensitive and diastereoselective assay system successfully evaluates the substrate scope of Rieske dioxygenases and determines the relative activity of a rationally designed Rieske dioxygenase variant library. The high throughput capacity of the assay system enables rapid and efficient substrate scope investigations and screening of large dioxygenase variant libraries.
Rational engineering of toluene dioxygenase expands the substrate scope of this enzyme, enabling the production of new, amide-functionalized chiral metabolites.
Natural products derived from biosynthetically apt microorganisms represent an important source for chemotherapeutic agents founded first via non-specific, cytotoxicity-guided isolation, then investigated for translational potential. Analyzing biosynthetic gene clusters within microbes predicts significant untapped potential of undiscovered therapeutically relevant natural products; however, stimulating biosynthesis of such compounds in sufficient quantities for isolation, structure determination, and biological assessment remains a gap. We address this with a bioactivity discovery pipeline that first utilizes Multiplexed Activity Profiling to identify stimulus-dependent induction of bioactive secondary metabolites via functional responses in human leukemia cell lines measured with fluorescence flow cytometry. Next, active extracts are analyzed via Multiplexed Activity Metabolomics, which correlates single cell assays with spectrally defined chromatographic arrays to identify bioactive metabolomic features prior to isolation. Two experimental case studies using this workflow with cave-microbe extracts identified new molecular phenotypes of the pyridine-pyrrolidine alkaloid siderochelin and the pyrrolopyrrole-functionalized anthracycline isoquinocycline B. Finally, we investigated the effects of anthracycline functionalization on human primary cells using single cell mass cytometry to understand if changes in anthracycline aglycon structure and glycosylation impacted cell selectivity. Despite sharing an anthracyclinone pharmacophore core, variants differentially impacted responses of leukemia cell populations within and among acute myeloid leukemia (AML) patient samples. This suggests pharmacophore assumptions may not guide assessment of therapeutic potential for anthracyclines and that modest structural differences can elicit marked changes in cellular function in different patients. Taken together, the depth of information afforded by single cell molecular phenotype-based discovery and mass cytometry deep cell profiling provides new patient-level insight into biological mechanisms of new and previously discovered molecules that may find expanded use in the clinic.
Rieske dioxygenases are enzyme systems that have a long history of being applied as chiral, green chemical catalysts in the production of valuable building blocks for organic synthesis, owing to their ability to catalyze the cis‐dihydroxylation of aromatics. The practical utility of these catalysts, however, has been limited by restrictions on their substrate scope and selectivity. Recent studies have demonstrated the potential of modifying the substrate tunnel of oxidase enzymes to modulate the selectivity and activity of these enzymes for specific substrates. Herein, we report the targeted modification of residues lining the substrate tunnel of a representative and widely used Rieske dioxygenase, toluene dioxygenase (TDO). Several enzyme variants generated through modification of the residues lining the substrate tunnel demonstrated substantially improved activity over the wild‐type enzyme for multiple substrates. Homology modeling, docking studies, molecular dynamics simulations, and substrate tunnel analysis were applied in efforts to elucidate how the identified mutations resulted in improved activity. These analyses suggested that new interactions introduced along the substrate tunnel may explain the improved activity observed with the best‐performing enzyme variants.